Write in a clean editor, then format for Alzheimer's & Dementia in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Alzheimer's & Dementia is a peer-reviewed journal published by Wiley, covering Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Functional Brain Connectivity Studies. Over its lifetime it has published 66,062 papers, which have received 376,020 citations.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Alzheimer's & Dementia 12 (3): 45–58.
Formats any DOI in Alzheimer's & Dementia style. No sign-up. |
| Publishes research in | Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Functional Brain Connectivity Studies Neurological Disease Mechanisms and Treatments Cholinesterase and Neurodegenerative Diseases |
| ISSN | 1552-5260 |
| Citation impact (2-yr) | 1.85 |
| h-index | 228 |
| i10-index | 3,346 |
| Article processing charge | $4,000 |
| Top institutions publishing here | University of California, San Francisco |
| Journal website | onlinelibrary.wiley.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal…
In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is…
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be…
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National…
This report describes the public health impact of Alzheimer's disease, including incidence and prevalence, mortality rates, costs of care, and the overall impact on caregivers and society. It also examines in detail the financial impact of Alzheimer's on families, including annual costs to families and the difficult decisions families must often make to pay those…
